Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211432 · ClinicalTrials.gov registry record · Phase 2
Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
A Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00211432 is a Phase 2 study that has completed, run by Manhattan Eye, Ear & Throat Hospital. The registered enrollment target is 4 participants.
The verdict
NCT00211432, a Phase 2 study, has completed, sponsored by Manhattan Eye, Ear & Throat Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control pseudovitelliform detachment.
Interventions
- DRUG Anecortave Acetate Sterile Suspension (15 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211432
The ClinicalTrials.gov registry entry for NCT00211432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Manhattan Eye, Ear & Throat Hospital, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anecortave Acetate Sterile Suspension (15 mg) is the first listed.
NCT00211432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211432 about?
NCT00211432 is a clinical study titled "Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)". The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control pseudovitelliform detachment.
What is the current status of trial NCT00211432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2008-04. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00211432?
The interventions under investigation include: Anecortave Acetate Sterile Suspension (15 mg) (DRUG).
Who is sponsoring clinical trial NCT00211432?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.